Clinical Trial Update: Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

An open-label, non-randomized Phase 2 trial evaluating cisplatin in BRCA1-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)

Snippet

Sponsor: Pomeranian Medical University Szczecin | Conditions: BRCA1 Mutation, Metastatic Breast Cancer | Phase 2 | Status: COMPLETED